Popular Trials
Monoclonal Antibodies
Belimumab + Rituximab for Systemic Sclerosis
This trial will test whether a combination of Belimumab & Rituximab, given on top of standard Mycophenolate Mofetil therapy, can improve fibrosis in early diffuse cutaneous systemic sclerosis (dcSSc) patients.
Phototherapy
UVA-1 Phototherapy for Scleroderma
This trial will use a single-blind, prospective, randomized (dominant/non-dominant hand) comparator design to assess the effect of high dose (80-120 J/cm2) UVA1 therapy on hand function in scleroderma in a paired t-test design. This study will be placebo-controlled (with a UV-blocking gloved hand), cross-over, randomized clinical trial.
Popular Filters
Trials for Multiple Sclerosis Patients
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Behavioural Intervention
Behavioral Intervention for Multiple Sclerosis
This trial tests an online program to help people with MS become more active. The program aims to improve their mobility, thinking skills, and overall well-being by boosting their confidence and setting clear goals. Researchers believe this will lead to lasting positive changes in their physical activity and quality of life.
Trials for MS Patients
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Behavioural Intervention
Behavioral Intervention for Multiple Sclerosis
This trial tests an online program to help people with MS become more active. The program aims to improve their mobility, thinking skills, and overall well-being by boosting their confidence and setting clear goals. Researchers believe this will lead to lasting positive changes in their physical activity and quality of life.
Phase 3 Trials
Monoclonal Antibodies
Anifrolumab for Systemic Sclerosis
This trial is testing anifrolumab, an injectable medication, in adults with systemic sclerosis. The goal is to see if it can reduce immune system attacks to lessen symptoms and prevent further damage. Anifrolumab is a human monoclonal antibody that targets the type I interferon receptor and has been tested in multiple studies for systemic lupus erythematosus (SLE) and other autoimmune diseases.
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
mTOR inhibitor
Long-Term Safety of Everolimus for Tuberous Sclerosis
This trial is for patients with TSC and refractory seizures who are currently receiving everolimus treatment and are determined to be benefiting from it, in order to evaluate the long-term safety of the treatment.
Trials With No Placebo
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Procedure
Extracorporeal Photopheresis for Systemic Sclerosis
This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
Alkylating agents
Stem Cell Transplant for Scleroderma
This trial tests a treatment for systemic scleroderma involving stem cell collection, high-dose chemotherapy, and immune suppression, followed by returning the patient's own stem cells and using a maintenance drug to prevent disease recurrence. The treatment has shown a satisfactory risk-benefit ratio in earlier studies.
View More Related Trials
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
The quest for medical advancements and improved treatments is an ongoing journey, extending beyond specific conditions to encompass a wide range of health concerns. In this pursuit, several top hospitals are leading the way in clinical trials for undefined conditions. Massachusetts General Hospital in Boston stands out with four active trials focused on these elusive ailments. Known for their commitment to innovative research, this hospital's dedication shines through as they strive to unravel the mysteries surrounding unidentified diseases.
On the West Coast, Pacific Arthritis Care Center brings its expertise to bear on these enigmatic conditions as well. Located in Los Angeles, this center conducts four active clinical trials aimed at shedding light on undefined illnesses that continue to challenge the medical community.
Heading further east, Johns Hopkins University in Baltimore has also devoted significant resources toward understanding and treating unknown disorders. With three ongoing clinical trials dedicated to undefined conditions, this renowned institution showcases its commitment to pushing boundaries and seeking answers where there are none.
In Houston, The University of Texas Health Science Center is making substantial contributions by conducting two active clinical trials related to undisclosed diseases. Through rigorous scientific investigation and collaboration with experts from various fields, they aim to make significant breakthroughs that can positively impact patients' lives.
Across the Atlantic Ocean lies St. Joseph's Health Care Rheumatology Clinic in London—a notable player when it comes to tackling poorly understood illnesses head-on. This clinic actively engages in two mysterious condition-focused clinical trials while providing hope and support for patients grappling with unidentified health challenges.
As we navigate through uncharted territories within healthcare, these leading hospitals serve as beacons of progress—channeling their knowledge and expertise into finding solutions even when faced with uncertainty. The determination of researchers within these institutions reinforces their unwavering commitment towards uncovering answers that will ultimately improve countless lives impacted by undetermined conditions worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities emerge as prominent hubs for research. Los Angeles, California leads the way with 16 ongoing trials investigating treatments like MK-2225, HZN-825 QD, and MT-7117. Houston, Texas follows closely behind with 10 active trials focusing on interventions such as Peripheral Blood Stem Cell Transplantation and Transcutaneous Electrical Acustimulation (TEA). Additionally, Boston Massachusetts and Baltimore Maryland both offer opportunities for participation in 10 and 8 studies respectively. Finally, Cleveland Ohio presents promising options with its 7 current trials exploring treatments like TEPEZZA and efzofitimod 450 mg. These cities serve as important centers for cutting-edge research that contributes to the advancement of medical knowledge and potential breakthroughs in healthcare.
Which are the top treatments for undefined being explored in clinical trials?
Currently, there are several top treatments for undefined conditions being investigated in clinical trials. These include:
- Daratumumab: Being tested in six active trials and has a total of 134 breast cancer trials since 2012.
- Belantamab mafodotin: Under examination in four ongoing trials with a history of 26 breast cancer trials since its introduction in 2018.
- Lenalidomide: Engaged in three active breast cancer studies and has been part of 280 clinical trials across various conditions since its debut in 2003.
With each trial, researchers come closer to uncovering potential breakthroughs that may benefit patients facing undefined health challenges.
What are the most recent clinical trials for undefined?
Several exciting clinical trials have recently emerged, offering potential breakthroughs in the realm of undefined conditions. One promising study focuses on efzofitimod 450 mg, a Phase 2 trial that became available on September 1st, 2023. Additionally, Mycophenolate mofetil is being investigated as a treatment option through another Phase 2 trial for this condition. A Phase 3 trial involving Anifrolumab administered subcutaneously on a weekly basis also holds promise for patients with undefined conditions and became available on July 13th, 2023. These trials aim to provide valuable insights into potential treatments and improve patient outcomes in the face of this enigmatic ailment.
What undefined clinical trials were recently completed?
I apologize, but I cannot provide a specific answer to the question as it asks for "undefined" clinical trials. Could you please provide more information or specify which clinical trials you are referring to? That way, I can offer a clear and accurate response tailored to your query.